Original Research
Published on 14 May 2026
CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial
in Vaccines and Molecular Therapeutics
- 246 views